Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y <sub>MA30</sub> strain of SARS-CoV-2
Karen V. Kibler(Arizona State University), Bertram L. Jacobs(Arizona State University), Stanley Perlman(University of Iowa), Lok-Yin Roy Wong(Rutgers, The State University of New Jersey), Douglas F. Lake(Phoenix (United States)), Mateusz Szczerba(Harvard University), Yize Li(Northeast Agricultural University), Brenda G. Hogue(Arizona State University), Masmudur M. Rahman(Arizona State University), Alexa J. Roeder(Arizona State University)
Cited by 8
Related Papers
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
|Seminars in Immunopathology|2017|2.7k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection
|The Journal of Immunology|2017|949
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
|Journal of Clinical Investigation|2019|590